Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A)

The vaccine contains a de‑O‑acetylated polysaccharide from N. meningitidis group C linked to tetanus toxoid. This conjugate is recognized by the immune system, prompting T‑cell help and stimulating B‑cells to produce high‑affinity IgG antibodies that neutralise the bacteria and provide long‑lasting protection.

The specific dosing schedule for Neisvac-C is determined by the prescribing clinician based on age, local immunisation guidelines, and risk factors. Typically, a primary series followed by booster doses is recommended, but the exact regimen should be confirmed by a qualified health professional.

Safety data in pregnancy are limited, so the vaccine should be used only if the expected benefit outweighs potential risks. Breastfeeding is not a contraindication; the vaccine can be administered while nursing, but clinicians should consider individual circumstances.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Neisvac-C is a conjugate vaccine targeting serogroup C, offering T‑cell‑dependent immunity and longer‑lasting protection compared with plain polysaccharide vaccines. It differs from quadrivalent conjugate vaccines that also cover serogroups A, W and Y, making it a focused option when only serogroup C protection is needed.

Neisvac-C must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

The vaccine is given by intramuscular injection, usually into the deltoid muscle of the upper arm. Administration is performed by a qualified healthcare professional following aseptic technique and the dosing schedule prescribed by the clinician.

The most serious adverse events include severe allergic reactions such as anaphylaxis, rare neurological conditions like Guillain‑Barré syndrome, and, in very uncommon cases, seizures. Immediate medical attention is required if any of these symptoms appear after vaccination.

Individuals with a known severe allergy to any component of the vaccine, including the tetanus toxoid carrier, should not receive Neisvac-C. It is also contraindicated in persons who have experienced a previous anaphylactic reaction to a meningococcal conjugate vaccine.